In last trading session, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) saw 2.23 million shares changing hands with its beta currently measuring 1.34. Company’s recent per share price level of $6.07 trading at -$0.22 or -3.50% at ring of the bell on the day assigns it a market valuation of $1.86B. That closing price of AMRX’s stock is at a discount of -6.43% from its 52-week high price of $6.46 and is indicating a premium of 79.57% from its 52-week low price of $1.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.5 million shares which gives us an average trading volume of 1.46 million if we extend that period to 3-months.
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) trade information
Upright in the red during last session for losing -3.50%, in the last five days AMRX remained trading in the green while hitting it’s week-highest on Tuesday, 03/19/24 when the stock touched $6.07 price level, adding 6.04% to its value on the day. Amneal Pharmaceuticals Inc’s shares saw a change of 0.00% in year-to-date performance and have moved 10.36% in past 5-day. Amneal Pharmaceuticals Inc (NASDAQ:AMRX) showed a performance of 6.68% in past 30-days. Number of shares sold short was 1.83 million shares which calculate 1.33 days to cover the short interests.
Amneal Pharmaceuticals Inc (AMRX) estimates and forecasts
Statistics highlight that Amneal Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 42.15% of value to its shares in past 6 months, showing an annual growth rate of -17.19% while that of industry is 11.20. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -25.00% in the current quarter and calculating -26.30% decrease in the next quarter. This year revenue growth is estimated to rise 9.00% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $618.12 million for the same. And 4 analysts are in estimates of company making revenue of $650.37 million in the next quarter that will end on Jun 2024. Company posted $557.54 million and $599.05 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 10.90% while estimating it to be 8.60% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.74% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -8.93% while estimates for its earnings growth in next 5 years are of -1.50%.
AMRX Dividends
Amneal Pharmaceuticals Inc is more likely to be releasing its next quarterly report between February 29 and March 04 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Amneal Pharmaceuticals Inc (NASDAQ:AMRX)’s Major holders
Insiders are in possession of 53.15% of company’s total shares while institution are holding 36.13 percent of that, with stock having share float percentage of 77.11%. Investors also watch the number of corporate investors in a company very closely, which is 36.13% institutions for Amneal Pharmaceuticals Inc that are currently holding shares of the company. Fosun International Ltd is the top institutional holder at AMRX for having 21.52 million shares of worth $130.63 million. And as of Dec 30, 2023, it was holding 7.02% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 13.64 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 4.45% of outstanding shares, having a total worth of $82.81 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 4.06 million shares of worth $24.66 million or 1.33% of the total outstanding shares. The later fund manager was in possession of 3.53 million shares on Dec 30, 2023, making its stake of worth around $21.45 million in the company or a holder of 1.15% of company’s stock.
